ICOS Specific Neutra™ Antibody Products
Inducible T cell costimulator (ICOS), also known as AILIM, belongs to the CD28 cell-surface receptor family. It has two isoforms. Isoform 1 is a single-pass type I membrane protein and isoform 2 is a secreted protein. It is overexpressed in normal tissues such as whole blood, small intestine, and spleen. The interaction between ICOS and ICOSLG plays an important role in cancer immunotherapy.
Its Gene ID is 29851, OMIM ID is 604558, and UniProtKB ID is Q9Y6W8.
ICOS Signaling Pathway
The binding of ICOS by ICOSLG (B7H), a co-receptor shared with CD28, may provide signals that substitute for CD28 in regulating T-cell function.
ICOS may bind to p85 and activate the PDK1-PKB pathway, which is involved in the upregulation of cell metabolism and survival.
Upregulation of CD40L and ICOS plays a critical role in immune B cell activation and differentiation.
ICOS increases cytokine production of interferon-γ (IFN-γ), IL-4, and IL-10.
Fig.1 ICOS signaling pathways.1
Clinical Significance of ICOS
As a costimulatory receptor for T cell enhancement, the function of ICOS includes immune response regulation, endocytosis, and cell activation. ICOS may represent a new successful therapeutic prospect for cancer immunotherapy.
Antagonistic and agonistic anti-ICOS antibodies could be a good targeting strategy for cancer immunotherapy. The ICOS agonist antibodies could enhance inhibitory checkpoint blockade and inhibit immunosuppressive Tregs.
Functional analysis revealed that ICOS expression positively correlated with tumor mutation burden (TMB) in tumors such as breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), and acute myeloid leukemia (LAML). ICOS expression correlated favorably with microsatellite instability (MSI) in COAD and thyroid carcinoma (THCA).
Fig.2 Functional analysis of ICOS gene expression.2
Creative Biolabs offers numerous anti-ICOS antibodies angling in eight research areas. The high-quality anti-ICOS antibodies expressed recombinantly in mammalian cells are suitable for biomedical research and industrial applications.
Rudd, Christopher E., and Helga Schneider. "Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling." Nature Reviews Immunology 3.7 (2003): 544-556.
Zhao, Xiashuang.; et al. "Comprehensive analysis of the role of ICOS (CD278) in pan-cancer prognosis and immunotherapy." BMC cancer 23.1 (2023): 194.